CytomX Therapeutics (CTMX) Long-Term Deferred Tax (2018)

CytomX Therapeutics (CTMX) has 1 years of Long-Term Deferred Tax data on file, last reported at $87.6 million in Q4 2018.

• Quarterly Long-Term Deferred Tax changed N/A year-over-year to $87.6 million in Q4 2018, while the trailing twelve-month figure through Dec 2018 was $87.6 million (changed N/A YoY) and the FY2018 annual result came in at $87.6 million, changed N/A from the prior year.
• Long-Term Deferred Tax was little changed at $87.6 million in Q4 2018.
• In the past five years, Long-Term Deferred Tax ranged from a high of $87.6 million in Q4 2018 to a low of $87.6 million in Q4 2018.